This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pemán, J.
Right arrow Articles by Molina, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pemán, J.
Right arrow Articles by Molina, A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2006, p. 1912-1914, Vol. 44, No. 5
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.5.1912-1914.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

CASE REPORT

Spondylodiscitis Caused by Candida krusei: Case Report and Susceptibility Patterns

Javier Pemán,1* Isidro Jarque,2 María Bosch,1 Emilia Cantón,3 Miguel Salavert,4 Rosario de Llanos,5 and Araceli Molina1

Microbiology Department, La Fe University Hospital, Av. Campanar 21, 46009 Valencia, Spain,1 Hematology Department, La Fe University Hospital, Av. Campanar 21, 46009 Valencia, Spain,2 Microbiology Experimental Unit, La Fe University Hospital, Av. Campanar 21, 46009 Valencia, Spain,3 Infectious Diseases Unit, La Fe University Hospital, Av. Campanar 21, 46009 Valencia, Spain,4 IATA (CSIC), Aptdo. Correos 73, 46100 Burjassot, Spain5

Received 26 December 2005/ Accepted 22 February 2006

A 62-year-old man with amphotericin B-resistant Candida krusei spondylodiscitis, following an episode of candidemia caused by the same strain, was successfully treated with caspofungin plus voriconazole. Amphotericin B fungicidal concentrations were better predictors of the clinical outcome than were MICs. This is the first case of C. krusei spondylodiscitis reported in the literature.

* Corresponding author. Mailing address: Servicio de Microbiología, Hospital Universitario La Fe, Av. Campanar, 21, 46009 Valencia, Spain. Phone: 34 96 1973333. Fax: 34 96 1973177. E-mail: peman_jav{at}gva.es.

Journal of Clinical Microbiology, May 2006, p. 1912-1914, Vol. 44, No. 5
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.5.1912-1914.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Espinel-Ingroff, A., Johnson, E., Hockey, H., Troke, P. (2008). Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 61: 616-620 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Nagy, E., Dobiasova, S., Rinaldi, M., Barton, R., Veselov, A., the Global Antifungal Surveillance Group, (2008). Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46: 515-521 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»